Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-5918 in Advanced Solid Tumors or Hematologic Malignancies
NCT05415098Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of APG-5918 in nasopharyngeal carcinoma (NPC), prostate cancer (PCa), gastric cancer (GC) and 6 more (3 arms), sponsored by Ascentage Pharma. Primary endpoint: Dose-limiting Toxicity at 28 days. Started Sep 2022; status: recruiting.
02
Drugs
APG-5918
03
Conditions
nasopharyngeal carcinoma (NPC)prostate cancer (PCa)gastric cancer (GC)ovarian clear cell carcinoma (OCCC)mesothelioma
Beyond the preview
Go deeper on NCT05415098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415098.